DBV Technologies: management transactions · France · AMF

About DBV Technologies

DBV TECHNOLOGIES is a French biopharmaceutical company listed on Euronext Paris, focused on developing innovative treatments for food allergies and certain immunologic diseases. Founded in 2002 by pediatricians, the company was built around a clear scientific hypothesis: severe allergies may be treated more safely and effectively through epicutaneous immunotherapy. While its roots are in France, DBV Technologies has evolved into an international organization to support its clinical, regulatory and commercial programs, with a particularly important footprint in the United States, a key market for food-allergy therapies. The company now describes itself as a global clinical-stage biopharmaceutical group working to address conditions with significant unmet medical need. DBV’s business is centered on its proprietary Viaskin® platform, a patch-based delivery system designed to administer tiny amounts of allergen through the skin in order to retrain the immune system. This approach, known as epicutaneous immunotherapy or EPIT, is the company’s main technological differentiator. Its flagship development program targets peanut allergy, with Viaskin® Peanut as the lead candidate and versions tailored to different pediatric age groups. Beyond peanut allergy, DBV also intends to explore broader applications for its technology in inflammatory and autoimmune diseases, which expands the long-term commercial opportunity beyond the food-allergy segment. From a competitive standpoint, DBV Technologies occupies a distinctive niche in the European biotech landscape. It is a platform-focused specialist rather than a diversified drug developer, which can create substantial upside if clinical and regulatory milestones are achieved, but also implies a high-risk profile typical of late-stage biotechnology companies. The company has also administered more than one million patches to thousands of children across its clinical work, underlining the scale of its development experience. DBV Technologies has an international presence, with activities and expertise spread across Europe and North America. Its teams cover clinical development, regulatory affairs, medical affairs and commercial preparation, supporting both future product launch readiness and ongoing engagement with regulators, investigators and investors. Notable facts include its 2002 founding, its exclusive focus on EPIT, and its ambition to become the first company to commercialize an epicutaneous immunotherapy for peanut allergy. As such, DBV Technologies remains a science-driven growth story whose value creation depends largely on the success of the Viaskin® pipeline and the outcome of its clinical and regulatory efforts.